GI
TXMD icon

Gradient Investments’s TherapeuticsMD TXMD Stock Holding History

Gradient Investments’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-21
Closed -$2K – 1243
2019
Q4 		$2K Hold
21
– – ﹤0.01% 964
2019
Q3 		$4K Hold
21
– – ﹤0.01% 842
2019
Q2 		$3K Buy
+21
New +$3.76K ﹤0.01% 848

Other funds holding TXMD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gradient Investments's TXMD Position: Q1 2020 in Review

Gradient Investments sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 21 shares — an estimated $2K sold.

Gradient Investments first reported a position in TXMD in Q2 2019 and held it in 3 quarters. The position peaked at $4K in Q3 2019. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

  • Gradient Investments reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
  • Gradient Investments sold 21 TherapeuticsMD shares in Q1 2020, an estimated $2K.
  • Gradient Investments first reported a position in TherapeuticsMD in Q2 2019 and held it in 3 quarters.
  • Gradient Investments's TherapeuticsMD position peaked at $4K in Q3 2019.
  • 143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on Gradient Investments's 13F filing for Q1 2020, filed 7 Apr 2020.